UNSPSC 51333705: Prothipendyl

This classification denotes an antipsychotic agent with the molecular formula C16H19N3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5O6VWA87VA, chemically known as 10h-pyrido(3,2-b)(1,4)benzothiazine-10-propanamine, n,n-dimethyl- but generally known as prothipendyl, which bears US NIH Compound Identifier 14670. European Medicines Agency schedules Prothipendyl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10138MIG. The term PROTHIPENDYL is an International Non-Proprietary Name.

UNSPSC 51333705 Prothipendyl (Commodity) covers pharmaceutical products procured by state and local health agencies, though recent activity under this code name shows limited direct relevance—the tagged opportunities involve naloxone, generic multi-source pharmaceuticals, and over-the-counter products rather than prothipendyl specifically. State and local buyers using this code tier include county health departments, state health and human services commissions, and cooperative purchasing alliances serving multi-state public health networks. The actual procurement activity centers on pharmaceutical supply contracts for community health initiatives, pharmacy benefit programs, and authorized wholesaler distribution networks, with vendors required to meet FDA compliance, current Good Manufacturing Practices (cGMP), Drug Supply Chain Security Act (DSCSA) certification, and detailed product data submission including NDC codes, packaging configurations, and manufacturing locations.

Recent opportunities span Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, fixed-fee pricing, and a two-year initial term with one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, seeking information on direct contracting, negotiated net pricing models, and outcomes-based agreements outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products, requiring authorized wholesaler relationships with AmerisourceBergen, Cardinal Health, and Morris & Dickson, with pricing weighted 75 percent in evaluation and a 3 percent administrative fee on all purchases.